{
  "version": "1.1.0",
  "description": "Core prescribing cascade knowledge base for clinical decision support",
  "last_updated": "2025-01-01",
  "disclaimer": "For decision support only. Always verify with current clinical guidelines.",
  "cascades": [
    {
      "id": "CC001",
      "name_es": "AINE → Hipertensión → Antihipertensivo",
      "name_en": "NSAID → Hypertension → Antihypertensive",
      "index_drug_class": "NSAID",
      "index_drugs_examples": ["ibuprofen", "naproxen", "diclofenac", "meloxicam", "ketorolac", "celecoxib", "indomethacin", "piroxicam"],
      "ade_mechanism_es": "Inhibición de prostaglandinas → retención de sodio/agua → vasoconstricción → elevación de PA",
      "ade_mechanism_en": "Prostaglandin inhibition → sodium/water retention + vasoconstriction → BP elevation",
      "ade_es": "Elevación de tensión arterial",
      "ade_en": "Blood pressure elevation",
      "cascade_drug_class": "Antihypertensive",
      "cascade_drugs_examples": ["amlodipine", "enalapril", "lisinopril", "losartan", "valsartan", "hydrochlorothiazide", "bisoprolol", "atenolol", "furosemide", "doxazosin"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 7,
      "time_to_ade_typical_days_max": 90,
      "evidence_level": "A",
      "prevalence_es": "Muy común; uno de los cascadas más documentadas",
      "prevalence_en": "Very common; one of the most documented cascades",
      "clinical_note_es": "Considerar si los AINEs son realmente necesarios. En PVVIH, preferir paracetamol cuando sea posible.",
      "clinical_note_en": "Consider if NSAIDs are truly necessary. In PLHIV, prefer paracetamol when possible.",
      "references": ["Scott IA et al. Med J Aust 2013", "Lanas A et al. Aliment Pharmacol Ther 2003"]
    },
    {
      "id": "CC002",
      "name_es": "AINE → Síntomas GI → IBP",
      "name_en": "NSAID → GI Symptoms → PPI",
      "index_drug_class": "NSAID",
      "index_drugs_examples": ["ibuprofen", "naproxen", "diclofenac", "meloxicam", "aspirin", "ketorolac"],
      "ade_mechanism_es": "Inhibición de COX-1 gástrica → reducción de moco protector → irritación/úlcera GI",
      "ade_mechanism_en": "Gastric COX-1 inhibition → reduced protective mucus → GI irritation/ulceration",
      "ade_es": "Dispepsia, úlcera péptica, náuseas, dolor abdominal",
      "ade_en": "Dyspepsia, peptic ulcer, nausea, abdominal pain",
      "cascade_drug_class": "PPI",
      "cascade_drugs_examples": ["omeprazole", "pantoprazole", "lansoprazole", "esomeprazole", "rabeprazole"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 3,
      "time_to_ade_typical_days_max": 60,
      "evidence_level": "A",
      "prevalence_es": "Muy común; los IBP son frecuentemente prescritos innecesariamente",
      "prevalence_en": "Very common; PPIs are frequently prescribed unnecessarily",
      "clinical_note_es": "Si se suspende el AINE, el IBP puede no ser necesario. En PVVIH verificar interacciones de IBP con ARV.",
      "clinical_note_en": "If NSAID is stopped, the PPI may not be needed. In PLHIV verify PPI-ARV interactions.",
      "references": ["Lanas A et al. 2006", "Targownik LE et al. 2008"]
    },
    {
      "id": "CC003",
      "name_es": "IECA → Tos → Antitusivo / Cambio a ARA-II",
      "name_en": "ACE Inhibitor → Cough → Antitussive / Switch to ARB",
      "index_drug_class": "ACE inhibitor",
      "index_drugs_examples": ["enalapril", "lisinopril", "ramipril", "captopril", "perindopril", "fosinopril"],
      "ade_mechanism_es": "Acumulación de bradicinina → irritación de vías respiratorias → tos seca",
      "ade_mechanism_en": "Bradykinin accumulation → respiratory tract irritation → dry cough",
      "ade_es": "Tos seca persistente",
      "ade_en": "Persistent dry cough",
      "cascade_drug_class": "Antitussive",
      "cascade_drugs_examples": ["dextromethorphan", "codeine", "benzonatate", "guaifenesin"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 7,
      "time_to_ade_typical_days_max": 180,
      "evidence_level": "A",
      "prevalence_es": "10-15% de pacientes con IECAs desarrollan tos. Más frecuente en mujeres y pacientes asiáticos.",
      "prevalence_en": "10-15% of patients on ACE inhibitors develop cough. More common in women and Asian patients.",
      "clinical_note_es": "La solución correcta es cambiar el IECA por un ARA-II, no añadir antitusivo.",
      "clinical_note_en": "The correct solution is to switch ACE inhibitor to ARB, not add an antitussive.",
      "references": ["Dicpinigaitis PV. Chest 2006"]
    },
    {
      "id": "CC004",
      "name_es": "Antagonista del calcio → Edema maleolar → Diurético",
      "name_en": "Calcium Channel Blocker → Ankle Edema → Diuretic",
      "index_drug_class": "Calcium channel blocker",
      "index_drugs_examples": ["amlodipine", "nifedipine", "felodipine", "lercanidipine"],
      "ade_mechanism_es": "Vasodilatación arteriolar preferente → incremento de presión capilar → edema periférico",
      "ade_mechanism_en": "Preferential arteriolar vasodilation → increased capillary pressure → peripheral edema",
      "ade_es": "Edema de tobillos/piernas",
      "ade_en": "Ankle/leg edema",
      "cascade_drug_class": "Diuretic",
      "cascade_drugs_examples": ["furosemide", "hydrochlorothiazide", "indapamide", "spironolactone", "torasemide"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 14,
      "time_to_ade_typical_days_max": 120,
      "evidence_level": "A",
      "prevalence_es": "Ocurre en ~10% con amlodipino. El diurético trata el síntoma pero no la causa.",
      "prevalence_en": "Occurs in ~10% with amlodipine. Diuretic treats the symptom but not the cause.",
      "clinical_note_es": "Considerar reducción de dosis del ACa, cambio a dihidropiridina de menor efecto vasodilatador, o adición de IECA/ARA-II.",
      "clinical_note_en": "Consider reducing CCB dose, switching to less vasodilatory dihydropyridine, or adding ACEi/ARB.",
      "references": ["Elliott WJ. J Clin Hypertens 2003"]
    },
    {
      "id": "CC005",
      "name_es": "Corticosteroide → Hiperglucemia → Antidiabético",
      "name_en": "Corticosteroid → Hyperglycemia → Antidiabetic",
      "index_drug_class": "Corticosteroid",
      "index_drugs_examples": ["prednisone", "prednisolone", "methylprednisolone", "dexamethasone", "hydrocortisone", "betamethasone"],
      "ade_mechanism_es": "Resistencia a insulina inducida por glucocorticoides → hiperglucemia",
      "ade_mechanism_en": "Glucocorticoid-induced insulin resistance → hyperglycemia",
      "ade_es": "Hiperglucemia, diabetes esteroidea",
      "ade_en": "Hyperglycemia, steroid-induced diabetes",
      "cascade_drug_class": "Antidiabetic",
      "cascade_drugs_examples": ["metformin", "glipizide", "glibenclamide", "sitagliptin", "insulin glargine", "insulin aspart"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 1,
      "time_to_ade_typical_days_max": 30,
      "evidence_level": "A",
      "prevalence_es": "Ocurre en ~20-50% de los tratados con corticoides. En PVVIH puede exacerbarse con inhibidores de proteasa.",
      "prevalence_en": "Occurs in ~20-50% treated with corticosteroids. In PLHIV may be exacerbated by protease inhibitors.",
      "clinical_note_es": "Revisar si el corticoide puede reducirse/suspenderse. La insulina suele ser más apropiada que la metformina para la hiperglucemia esteroidea.",
      "clinical_note_en": "Review whether corticosteroid can be reduced/discontinued. Insulin is often more appropriate than metformin for steroid-induced hyperglycemia.",
      "references": ["Clore JN, Thurby-Hay L. Ann Pharmacother 2009"]
    },
    {
      "id": "CC006",
      "name_es": "Corticosteroide → Osteoporosis → Bisfosfonato",
      "name_en": "Corticosteroid → Osteoporosis → Bisphosphonate",
      "index_drug_class": "Corticosteroid",
      "index_drugs_examples": ["prednisone", "prednisolone", "methylprednisolone", "dexamethasone"],
      "ade_mechanism_es": "Inhibición de osteoblastos + activación de osteoclastos → pérdida ósea",
      "ade_mechanism_en": "Osteoblast inhibition + osteoclast activation → bone loss",
      "ade_es": "Osteoporosis inducida por corticoides",
      "ade_en": "Corticosteroid-induced osteoporosis",
      "cascade_drug_class": "Bisphosphonate",
      "cascade_drugs_examples": ["alendronate", "risedronate", "zoledronic acid", "ibandronate"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 90,
      "time_to_ade_typical_days_max": 730,
      "evidence_level": "A",
      "prevalence_es": "Muy común en uso crónico de corticoides. En PVVIH, la osteoporosis es multifactorial (ARV, corticoides, inflamación crónica).",
      "prevalence_en": "Very common with chronic corticosteroid use. In PLHIV, osteoporosis is multifactorial (ARV, corticosteroids, chronic inflammation).",
      "clinical_note_es": "Puede ser una prescripción apropiada si el corticoide es necesario a largo plazo. Evaluar el contexto.",
      "clinical_note_en": "May be an appropriate prescription if corticosteroid is needed long-term. Evaluate the context.",
      "references": ["Weinstein RS. Endocrinol Metab Clin North Am 2012"]
    },
    {
      "id": "CC007",
      "name_es": "Tiazida → Hiperuricemia/Gota → Alopurinol/AINE",
      "name_en": "Thiazide → Hyperuricemia/Gout → Allopurinol/NSAID",
      "index_drug_class": "Thiazide diuretic",
      "index_drugs_examples": ["hydrochlorothiazide", "chlorthalidone", "indapamide"],
      "ade_mechanism_es": "Reducción de excreción renal de urato → hiperuricemia → ataque de gota",
      "ade_mechanism_en": "Reduced renal urate excretion → hyperuricemia → gout attack",
      "ade_es": "Hiperuricemia, artritis gotosa",
      "ade_en": "Hyperuricemia, gouty arthritis",
      "cascade_drug_class": "Urate-lowering therapy / NSAID",
      "cascade_drugs_examples": ["allopurinol", "febuxostat", "colchicine", "indomethacin", "prednisolone"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 30,
      "time_to_ade_typical_days_max": 365,
      "evidence_level": "B",
      "prevalence_es": "Las tiazidas aumentan el riesgo de gota en ~50%. Considerar diurético alternativo.",
      "prevalence_en": "Thiazides increase gout risk by ~50%. Consider alternative diuretic.",
      "clinical_note_es": "Si la tiazida puede suspenderse, los niveles de urato podrían normalizarse. Evaluar indicación.",
      "clinical_note_en": "If thiazide can be stopped, urate levels may normalize. Evaluate indication.",
      "references": ["Choi HK et al. BMJ 2012"]
    },
    {
      "id": "CC008",
      "name_es": "Opioide → Estreñimiento → Laxante",
      "name_en": "Opioid → Constipation → Laxative",
      "index_drug_class": "Opioid analgesic",
      "index_drugs_examples": ["morphine", "oxycodone", "fentanyl", "tramadol", "codeine", "buprenorphine", "methadone"],
      "ade_mechanism_es": "Activación de receptores mu opioides en plexo entérico → reducción del peristaltismo → estreñimiento",
      "ade_mechanism_en": "Activation of mu-opioid receptors in enteric plexus → reduced peristalsis → constipation",
      "ade_es": "Estreñimiento inducido por opioides",
      "ade_en": "Opioid-induced constipation (OIC)",
      "cascade_drug_class": "Laxative",
      "cascade_drugs_examples": ["lactulose", "macrogol", "bisacodyl", "senna", "sodium docusate", "naloxegol", "methylnaltrexone"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 1,
      "time_to_ade_typical_days_max": 14,
      "evidence_level": "A",
      "prevalence_es": "Ocurre en >40% de pacientes con opioides crónicos. El laxante está indicado profilácticamente.",
      "prevalence_en": "Occurs in >40% of patients on chronic opioids. Laxative is indicated prophylactically.",
      "clinical_note_es": "En este caso el laxante puede ser apropiado. Evaluar si el opioide puede reducirse o suspenderse.",
      "clinical_note_en": "In this case the laxative may be appropriate. Evaluate if the opioid can be reduced or stopped.",
      "references": ["Pappagallo M. Am J Surg 2001"]
    },
    {
      "id": "CC009",
      "name_es": "Antipsicótico → Síntomas extrapiramidales → Anticolinérgico",
      "name_en": "Antipsychotic → Extrapyramidal Symptoms → Anticholinergic",
      "index_drug_class": "Antipsychotic",
      "index_drugs_examples": ["haloperidol", "chlorpromazine", "olanzapine", "risperidone", "quetiapine", "aripiprazole"],
      "ade_mechanism_es": "Bloqueo dopaminérgico D2 en vía nigroestriada → síntomas extrapiramidales",
      "ade_mechanism_en": "D2 dopaminergic blockade in nigrostriatal pathway → extrapyramidal symptoms",
      "ade_es": "Parkinsonismo, distonía, acatisia",
      "ade_en": "Parkinsonism, dystonia, akathisia",
      "cascade_drug_class": "Anticholinergic / Antiparkinsonian",
      "cascade_drugs_examples": ["biperiden", "trihexyphenidyl", "benztropine", "procyclidine"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 3,
      "time_to_ade_typical_days_max": 60,
      "evidence_level": "A",
      "prevalence_es": "Más frecuente con antipsicóticos típicos y altas dosis. Valorar cambio a antipsicótico con menor riesgo EPS.",
      "prevalence_en": "More common with typical antipsychotics and high doses. Consider switching to antipsychotic with lower EPS risk.",
      "clinical_note_es": "Los anticolinérgicos tienen muchos efectos adversos propios (confusión, retención urinaria, glaucoma). Evitar en mayores.",
      "clinical_note_en": "Anticholinergics have many adverse effects themselves (confusion, urinary retention, glaucoma). Avoid in elderly.",
      "references": ["Kane JM et al. J Clin Psychiatry 2009"]
    },
    {
      "id": "CC010",
      "name_es": "ISRS → Insomnio → Hipnótico/Sedante",
      "name_en": "SSRI → Insomnia → Hypnotic/Sedative",
      "index_drug_class": "SSRI",
      "index_drugs_examples": ["fluoxetine", "sertraline", "paroxetine", "citalopram", "escitalopram", "fluvoxamine"],
      "ade_mechanism_es": "Activación serotoninérgica → estimulación central → insomnio, especialmente al inicio",
      "ade_mechanism_en": "Serotonergic activation → central stimulation → insomnia, especially at initiation",
      "ade_es": "Insomnio, alteraciones del sueño",
      "ade_en": "Insomnia, sleep disturbances",
      "cascade_drug_class": "Hypnotic / Sedative",
      "cascade_drugs_examples": ["zolpidem", "lorazepam", "alprazolam", "clonazepam", "diazepam", "melatonin", "mirtazapine", "trazodone"],
      "plausibility": "medium",
      "time_to_ade_typical_days_min": 1,
      "time_to_ade_typical_days_max": 30,
      "evidence_level": "B",
      "prevalence_es": "El insomnio puede ser parte de la depresión subyacente, no solo del ISRS. Contextualizar.",
      "prevalence_en": "Insomnia may be part of the underlying depression, not just the SSRI. Contextualize.",
      "clinical_note_es": "Los hipnóticos tienen riesgo de dependencia. Considerar higiene del sueño, cambio de hora de administración del ISRS o cambio de antidepresivo.",
      "clinical_note_en": "Hypnotics carry dependency risk. Consider sleep hygiene, changing SSRI timing, or switching antidepressant.",
      "references": ["Fava M et al. J Clin Psychiatry 2006"]
    },
    {
      "id": "CC011",
      "name_es": "Inhibidor de colinesterasa → Incontinencia urinaria → Anticolinérgico",
      "name_en": "Cholinesterase Inhibitor → Urinary Incontinence → Anticholinergic",
      "index_drug_class": "Cholinesterase inhibitor",
      "index_drugs_examples": ["donepezil", "rivastigmine", "galantamine"],
      "ade_mechanism_es": "Exceso colinérgico vesical → contracciones involuntarias del detrusor → incontinencia",
      "ade_mechanism_en": "Bladder cholinergic excess → involuntary detrusor contractions → urge incontinence",
      "ade_es": "Incontinencia urinaria de urgencia, urgencia miccional",
      "ade_en": "Urge urinary incontinence, urinary urgency",
      "cascade_drug_class": "Anticholinergic (urinary)",
      "cascade_drugs_examples": ["oxybutynin", "tolterodine", "solifenacin", "fesoterodine", "darifenacin"],
      "plausibility": "high",
      "time_to_ade_typical_days_min": 7,
      "time_to_ade_typical_days_max": 90,
      "evidence_level": "A",
      "prevalence_es": "Paradójico: el anticolinérgico antagoniza directamente el efecto del inhibidor de colinesterasa en el SNC.",
      "prevalence_en": "Paradoxical: the anticholinergic directly antagonizes the cholinesterase inhibitor's CNS effect.",
      "clinical_note_es": "Cascada particularmente problemática: el tratamiento de la incontinencia reduce la eficacia del tratamiento del Alzheimer.",
      "clinical_note_en": "Particularly problematic cascade: treating incontinence reduces effectiveness of Alzheimer's treatment.",
      "references": ["Gill SS et al. Arch Intern Med 2005"]
    },
    {
      "id": "CC012",
      "name_es": "Metformina → Síntomas GI → Antidiarreico/Antiespasmódico",
      "name_en": "Metformin → GI Symptoms → Antidiarrheal/Antispasmodic",
      "index_drug_class": "Biguanide",
      "index_drugs_examples": ["metformin"],
      "ade_mechanism_es": "Alteración de la microbiota intestinal y motilidad GI → diarrea, náuseas, dolor abdominal",
      "ade_mechanism_en": "GI microbiota alteration and motility changes → diarrhea, nausea, abdominal pain",
      "ade_es": "Diarrea, náuseas, meteorismo, dolor abdominal",
      "ade_en": "Diarrhea, nausea, bloating, abdominal pain",
      "cascade_drug_class": "Antidiarrheal / Antispasmodic",
      "cascade_drugs_examples": ["loperamide", "bismuth subsalicylate", "hyoscine", "mebeverine"],
      "plausibility": "medium",
      "time_to_ade_typical_days_min": 1,
      "time_to_ade_typical_days_max": 60,
      "evidence_level": "B",
      "prevalence_es": "Los síntomas GI son muy frecuentes con metformina (hasta 30%), especialmente al inicio. Suelen mejorar con el tiempo.",
      "prevalence_en": "GI symptoms are very common with metformin (up to 30%), especially at initiation. Usually improve over time.",
      "clinical_note_es": "Solución preferida: formulación de liberación prolongada o reducción de dosis, no añadir antidiarreico.",
      "clinical_note_en": "Preferred solution: extended-release formulation or dose reduction, not adding an antidiarrheal.",
      "references": ["Bailey CJ et al. Lancet 1996"]
    }
  ]
}
